Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Background KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an
aggressive disease with 3-year event-free survival below 40%. Most relapses occur during …

Bispecific antibodies (BsAbs) are antibodies with two binding sites directed at two different
antigens or two different epitopes on the same antigen. The clinical therapeutic effects of …

Importance Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia
(B-ALL) in children, adolescents, and young adults is associated with high rates of severe …

Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

PURPOSE CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates
in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but …

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

PURPOSE CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab
effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia …